Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (182)	7/10/2000 3:18:35 PM
From: RWReeves	Read Replies (1) \| Respond to of 184

Oh-Oh. T00-32 Print Media: 301-827-6242 July 10, 2000 Broadcast Media: 301-827-3434 Consumer Inquiries: 888-INFO-FDA NATIONWIDE RECALL OF SANGCYA ORAL SOLUTION The Food and Drug Administration today announced the nationwide recall of SangCya® oral solution, a generic version of the anti-rejection drug cyclosporine (Neoral® oral solution), because of clinical evidence that the generic drug's availability is reduced relative to Neoral® oral solution if the drug is administered with apple juice. Patients taking cyclosporine capsules are not affected by this recall. SangStat Medical Corporation of Fremont, California, the makers of SangCya®, recently informed the FDA about a study that was completed before the approval of the application. The data from this clinical study showed that taking SangCya® oral solution with apple juice diminishes its absorption relative to Neoral® oral solution. Because the drug's labeling suggests that it be taken with apple or -More- Page 2, T00-32 , SANGFCYA RECALL orange juice, the agency asked the sponsor to recall the product. Since it is recognized that some patients may be adversely affected by abruptly changing from SangCya® oral solution to another cyclosporine product, FDA will allow the product to remain in pharmacies and hospitals. This continued availability should allow a smooth transition of patients from the SangCya® product to another cyclosporine product. FDA is reviewing all data related to this product and will take any appropriate further steps needed to assure the safety patients. In the meantime, patients taking cyclosporine oral solution should consult with their health care provider about their treatment. Patients taking SangCya® oral solution should not change how they are taking their drug without talking to their health care provider. #### Not a big deal but enough to knock the wind out of it.. RWR